## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Patent Docket: P1093P1

## **Listing of Claims:**

- 34. (Currently Amended) Isolated nucleic acid encoding a humanized variant of a parent anti-VEGF antibody which parent antibody comprises non-human variable domains, wherein said humanized variant binds human VEGF and comprises the following heavy chain Complementary Determining Region (CDR) amino acid sequences: SEQ ID NO:128 as CDRH1, SEQ ID NO:2 as CDRH2 and SEQ ID NO:129 as CDRH3:

  (a) binds human VEGF with a K<sub>d</sub> value of no more than about 1 x 10 sM, said K<sub>d</sub> value being no more than about 6 fold of the K<sub>d</sub> value of said parent antibody;


  (b) has an ED50 value of no more than about 5nM for inhibiting VEGF induced proliferation of endothelial cells *in vitro*; and

  (c) inhibits VEGF induced angiogenesis *in vivo*, wherein 5mg/kg of said humanized variant inhibits at least about 50% of tumor growth in an A673 *in vivo* tumor model.
- 35. (Previously presented) A vector comprising the nucleic acid of claim 34.
- 36. (Previously presented) A host cell comprising the vector of claim 35.
- 37. (Previously presented) A process of producing a humanized anti-VEGF antibody comprising culturing the host cell of claim 36 so that the nucleic acid is expressed.
- 38. (Previously presented) The process of claim 37 further comprising recovering the humanized anti-VEGF antibody from the host cell culture.

Please add the following new claims: (number following non-elected claims 39-42)

43. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant further comprises the following light chain Complementary Determining Region (CDR) amino acid sequences: SEQ ID NO:4 as CDRL1, SEQ ID NO:5 as CDRL2 and SEQ ID NO:6 as CDRL3.

Patent Docket: P1093P1



- 45. (NEW) The isolated nucleic acid of claim 43, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:116 and a light chain variable domain sequence of SEQ ID NO:115.
- 46. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:125.
  - 47. (NEW) The isolated nucleic acid of claim 43, wherein the humanized variant comprises a light chain variable domain sequence of SEQ ID NO:124.
  - 48. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH1 sequence of SEQ ID NO:1.

(NEW) The isolated nucleic acid of claim 34, wherein the humanized variant comprises a GDRH1 sequence of SEQ ID NO:126.

- 50. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH3 sequence of SEQ ID NO:3.
- 51. (NEW) The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH3 sequence of SEQ ID NO:127.

TROUGHT CHANGE CHANGE CHANGE CHANGE CHANGE COR

## APPENDIX Clean Set of All Pending Claims

Patent Docket: P1093P1

 $\mathcal{D}_{\mathsf{I}}$ 

- 34. Isolated nucleic acid encoding a humanized variant of a parent anti-VEGF antibody which parent antibody comprises non-human variable domains, wherein said humanized variant binds human VEGF and comprises the following heavy chain Complementary Determining Region (CDR) amino acid sequences: SEQ ID NO:128 as CDRH1, SEQ ID NO:2 as CDRH2 and SEQ ID NO:129 as CDRH3.
- 35. A vector comprising the nucleic acid of claim 34.
- 36. A host cell comprising the vector of claim 35.
- 37. A process of producing a humanized anti-VEGF antibody comprising culturing the host cell of claim 36 so that the nucleic acid is expressed.
- 38. The process of claim 37 further comprising recovering the humanized anti-VEGF antibody from the host cell culture.
- 43. The isolated nucleic acid of claim 34, wherein the humanized variant further comprises the following light chain Complementary Determining Region (CDR) amino acid sequences: SEQ ID NO:4 as CDRL1, SEQ ID NO:5 as CDRL2 and SEQ ID NO:6 as CDRL3.



- 44. The isolated nucleic acid of claim 43, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:7 and a light chain variable domain sequence of SEQ ID NO:8.
- 45. The isolated nucleic acid of claim 43, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:116 and a light chain variable domain sequence of SEQ ID NO:115.
- 46. The isolated nucleic acid of claim 34, wherein the humanized variant comprises a heavy chain variable domain sequence of SEQ ID NO:125.

Appl. No. 08/908,469 Amdt. dated August 15, 2005 Response to Office Action mailed on July 9, 2002

47. The isolated nucleic acid of claim 43, wherein the humanized variant comprises a light chain variable domain sequence of SEQ ID NO:124.

Patent Docket: P1093P1

- 48. The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH1 sequence of SEQ ID NO:1.
- 49. The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH1 sequence of SEQ ID NO:126.
- 50. The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH3 sequence of SEQ ID NO:3.
- 51. The isolated nucleic acid of claim 34, wherein the humanized variant comprises a CDRH3 sequence of SEQ ID NO:127.

